Keyphrases
Enhanced Migration
100%
Matrix Metalloproteinases
100%
Tumor Cell Density
100%
Interleukin-6
42%
Metastasis
28%
Interleukin-8
28%
Cancer Cells
14%
Pharmacological Intervention
14%
Tumor Cells
14%
Tocilizumab
14%
Cell Density
14%
Primary Tumor
14%
Signaling Mechanism
14%
Density Condition
14%
Human Trials
14%
Multiple Persons
14%
Drug Resistance
14%
High Cell Density
14%
Metastatic Cancer
14%
Mouse Xenograft Model
14%
Cognate Receptors
14%
Density Change
14%
Early Growth
14%
Bryostatin
14%
Initial Seeding
14%
Dual Inhibition
14%
Migratory Phenotype
14%
JAK2-STAT3
14%
Interleukin-8 Receptor
14%
Batimastat
14%
Secondary Tumor
14%
Reparixin
14%
Matrix Metalloproteinase Inhibitors
14%
Marimastat
14%
Low Cell numbers
14%
Medicine and Dentistry
Tumor Cell
100%
Matrix Metalloproteinase
100%
Cell Density
100%
Metastatic Carcinoma
42%
Interleukin 6
42%
Interleukin 8
28%
Neoplasm
14%
Cancer Cell
14%
Clinical Trial
14%
Xenograft
14%
Tocilizumab
14%
Primary Tumor
14%
Signaling Mechanism
14%
Interleukin 8 Receptor
14%
Marimastat
14%
Bryostatin
14%
Reparixin
14%
Batimastat
14%
Cipemastat
14%
Matrix Metalloproteinase Inhibitor
14%
Drug Resistance
14%
Janus Kinase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Matrix Metalloproteinase
100%
Interleukin 6
42%
Interleukin 8
28%
Mouse
14%
Clinical Trial
14%
Bryostatin
14%
Malignant Neoplasm
14%
Metastasis
14%
Marimastat
14%
Matrix Metalloproteinase Inhibitor
14%
Cipemastat
14%
Reparixin
14%
Batimastat
14%
Interleukin 8 Receptor
14%
Primary Tumor
14%
Tocilizumab
14%
Janus Kinase
14%
Drug Resistance
14%
Biochemistry, Genetics and Molecular Biology
Cell Density
100%
Matrix Metalloproteinase
100%
Interleukin 8
42%
Interleukin 6
42%
Signaling Mechanism
14%
Clinical Trial
14%
Cancer Cell
14%
Mouse
14%
STAT3
14%
Matrix Metalloproteinase Inhibitor
14%
Drug Resistance
14%
Janus Kinase
14%